Current options and perspectives in the treatment of diabetic neuropathy

Current Pharmaceutical Design

Volumn 19, Issue 27, 2013, Pages 4981-5007

  Várkonyi, Tamás ^a   Putz, Zsuzsanna ^b   Keresztes, Katalin ^c   Martos, Tímea ^b   Lengyel, Csaba ^a   Stirban, Alin ^d   Jermendy, György ^e   Kempler, Peter ^b  

^a UNIVERSITY OF SZEGED   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c Szent Istvan and Szent Laszlo Hospitals   (Hungary)

^d Profil Institute for Metabolic Research   (Germany)

^e BAJCSY ZSILINSZKY HOSPITAL   (Hungary)

Author keywords

Alpha lipoic acid; Benfotiamine; Diabetic neuropathy; Duloxetine; Gabapentin; Pregabalin

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALDOSE REDUCTASE INHIBITOR; AMITRIPTYLINE; BENFOTIAMINE; CITALOPRAM; DULOXETINE; GABAPENTIN; GLUCOSE; HARKOSERIDE; HEMOGLOBIN A1C; HEXOSAMINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; IRBESARTAN; LAMOTRIGINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MORPHINE; OXCARBAZEPINE; PAROXETINE; POLYOL; PREGABALIN; PROTEIN KINASE C; THIOCTIC ACID; TOPIRAMATE; TRANDOLAPRIL; TRIACYLGLYCEROL; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

ALTERNATIVE MEDICINE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTONOMIC DYSFUNCTION; AUTONOMIC NEUROPATHY; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CONTROLLED CLINICAL TRIAL (TOPIC); DECARBOXYLATION; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIZZINESS; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; FATIGUE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; GLYCOLYSIS; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LONG TERM CARE; MAXIMUM TOLERATED DOSE; META ANALYSIS (TOPIC); METABOLIC REGULATION; MONONEUROPATHY; MONOTHERAPY; NAUSEA; NERVE CONDUCTION; NONHUMAN; OXIDATIVE STRESS; PALLIATIVE THERAPY; PATHOGENESIS; PENTOSE PHOSPHATE CYCLE; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHOTOTHERAPY; PHYSIOTHERAPY; POLYNEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT COURSE THERAPY; SIDE EFFECT; SLEEP TIME; SOMNOLENCE; THIAMINE DEFICIENCY; TRANSCUTANEOUS NERVE STIMULATION;

ANIMALS; ANTIOXIDANTS; CENTRAL NERVOUS SYSTEM AGENTS; DIABETIC NEUROPATHIES; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MOLECULAR TARGETED THERAPY; RISK FACTORS;

EID: 84881329001     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990310     Document Type: Article

References (274)

1. The therapy of neuropathy In: Jermendy Gy, Kempler P, Keresztes K, Pogátsa G, Várkonyi T, Winkler G. Neuropathies. A Global Clinical Guide. Kempler P, Várkonyi T, Eds. (Mon-Lib Bt): Zafír-Press, 2012; pp. 279-332.
2. Várkonyi T, Kempler P. Diabetic neuropathy: new strategies for treatment. Diabetes, Obesity and Metabolism 2008; 10: 99-108.
3. Kempler P, Stirban A, Tesfaye S, Czupryniak L, Gurieva I, Mankovsky BN, et al. Need for pathogenetically oriented therapy of neuropathy in diabetes mellitus. Diab Metab Heart, 2011; 20: 143-50.
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
5. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
6. Orchard TJ, Dorman JS, Maser RE, Becker DJ, Ellis D, LaPorte RE, et al. Factors associated with avoidance of severe complications after 25 yr of IDDM. Pittsburgh Epidemiology of Diabetes Complications Study I. Diabetes Care 1990; 13: 741-7.
7. EURODIAB IDDM Complications Study Group. Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study. Diabetologia 1994; 37: 278-86.
8. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulindependent diabetes mellitus: a randomized prospective 6-year study. Diab Res Clin Pract 1995; 28: 103-17.
9. The Diabetes Control and Complications Trial Research Group: The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995; 122: 561-8.
10. The Diabetes Control and Complications Trial Research Group: The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia 1998; 41: 416-23.
11. Epidemiology of Diabetes Interventions and Complications (EDIC): Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999; 22: 99-111.
12. Martin CL, Albers J, Herman WH, Cleary P, Waberski B, Greene DA, et al. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 2006; 29: 340-4.
13. Albers JW, Herman WH, Pop-Busui R, Feldman EL, Martin CL, Cleary PA, et al. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care 2010; 33: 1090-6.
14. Pop-Busui R, Low PA, Waberski BH, Martin CL, Albers JW, Feldman EL, et al. Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). Circulation 2009; 119: 2886-93.
15. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-53.
16. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al on behalf of the UKPDS Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. Br Med J 2000; 321: 405-12.
17. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
18. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-89.
19. Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012; DOI: 10.1002/14651858.CD007543.pub2
20. Greene DA, Lattimer SA, Sima AAF. Are disturbances of sorbitol, phosphoinositide, Na-K-ATPase regulation involved in pathogenesis of diabetic neuropathy? Diabetes 1988; 37: 688-93.
21. Maser RE, Pfeifer AM, Dorman SJ, Kuller HL. Diabetic autonomic neuropathy and cardiovascular risk. Pittsburgh Epidemilogy of Diabetes Complications Study III. Arch Intern Med 1990; 150: 1218-22.
22. Tesfaye S, Chatuverdi N, Eaton SE, Ward DJ, Manes C, Ionescu-Triviste C, et al. Vascular risk factors and diabetic neuropathy. N Eng J Med 2005; 352: 341-50.
23. Kempler P, Tesfaye S, Chatuverdi N, Stevens LK, Webb DJ, Eaton S, et al. Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complication Study. Diabet Med 2002; 19: 900-9.
24. Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia 1996; 39: 1377-84.
25. Witte DR, Tesfaye S, Chaturvedi N, Eaton SEM, Kempler P, Fuller JH, et al. Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. Diabetologia 2005; 48: 164-71.
26. Elliot J, Tesfaye S, Chaturvedi N, Gandhi RA, Stevens LK, Emery C, et al. Large fiber dysfunction in diabetic peripheral neuropathy is predicted by cardiovascular risk factors. Diabetes Care 2009; 32: 1896-1900
27. Keresztes K, Istenes I, Hermányi Zs, Vargha P, Barna I, Kempler P. Risk factors of autonomic and sensory nerve dysfunction in patients with newly diagnosed type 1 diabetes. Diabetes Care 2003; 26: 2213.
28. Gaede P, Vedel P, Larsen N, Jensen G, Parving HH, Pederson O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Eng J Med 2003; 348: 383-93.
29. Bergström B, Lijla B, Österlin S, Sundkvist G. Autonomic neuropathy in non-insulin dependent (Type 2) diabetes mellitus. Possible influence of obesity. J Intern Med 1990; 227: 57-63.
30. Rossi M, Marti G, Ricordi L, Fornasari G, Finardi G, Frationo P, et al. Cardiac autonomic dysfunction in obese subjects. Clin Sci 1989; 4: 567-72.
31. Gottsater A, Ahmed M, Fernlund P, Sundkvist G. Autonomic neuropathy in type 2 diabetic patients is associated with hyperinsulinaemia and hypertrigliceridaemia. Diabet Med 1999; 16: 49-54.
32. Spallone V, Maiello MR, Cicconetti E, Menzinger G. Autonomic neuropathy and cardiovascular risk factors in insulin dependent and non-insulin-dependent diabetes. Diab Res Clin Pract 1997; 34: 169-79.
33. Chalk C, Benstead TJ, Moore F. Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. Cochrane Database Syst Rev. 2007 Oct 17; (4): CD004572
34. Hotta N, Toyota T, Matsuoka K, Shigeta Y, Kikkawa R, Kaneko T, et al. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care 2001; 24: 1776-82.
35. Bril V, Hirose T, Tomioka S, Buchanan R; Ranirestat Study Group. Ranirestat for the management of diabetic sensorimotor polyneuropathy. Diabetes Care 2009; 32: 1256-60.
36. Ramirez MA, Borja NL. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy. Pharmacotherapy 2008; 28: 646-55.
37. Sharma SR, Sharma N. Epalrestat, an aldose reductase inhibitor, in diabetic neuropathy: An Indian perspective. Ann Indian Acad Neurol 2008; 11: 231-5.
38. Hotta N, Akanuma Y, Kawamori R, Matsuoka K, Oka Y, Shichiri M, et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care 2006; 29: 1538-44.
39. Ziegler D. Diabetic cardiovascular autonomic neuropathy: prognosis, diagnosis and treatment. Diabetes Metab Rev 1994; 10: 339-83.
40. Schmidt RE, Dorsey DA, Beaudet LN, Parvin CA, Yarasheski KE, Smith SR, et al. A potent sorbitol dehydrogenase inhibitor exacerbates sympathetic autonomic neuropathy in rats with streptozotocin-induced diabetes. Exp Neurol 2005; 192: 407-419.
41. Ramana KV, Srivastava SK. Aldose reductase: a novel therapeutic target for inflammatory pathologies. Int J Biochem Cell Biol. 2010; 42: 17-20.
42. Srivastava SK, Yadav UC, Reddy AB, Saxena A, Tammali R, Shoeb M, et al. Aldose reductase inhibition suppresses oxidative stress-induced inflammatory disorders. Chem Biol Interact 2011; 191: 330-8.
43. Singleton CK, Martin PR. Molecular mechanisms of thiamine utilization. Curr Mol Med 2001; 1: 197-207.
44. Volvert ML, Seyen S, Piette M, Evrard B, Gangolf M, Plumier JC, et al. Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives. BMC Pharmacol 2008; 8:10.
45. Rindi G. Thiamin absorption by small intestine. Acta Vitaminol Enzymol 1984; 6:47-55.
46. Loew D. Pharmacokinetics of thiamine derivatives especially of benfotiamine. Int J Clin Pharmacol Ther 1996; 34:47-50.
47. Schreeb KH, Freudenthaler S, Vormfelde SV, Gundert-Remy U, Gleiter CH. Comparative bioavailability of two vitamin B1 preparations: benfotiamine and thiamine mononitrate. Eur J Clin Pharmacol 1997; 52: 319-20.
48. Brownlee M: The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54:1615-25.
49. Alkhalaf A, Klooster A, van Oereven W, Achenbach U, Kleefstra N, Slingerland RJ, et al. A double-blind, randomized, placebocontrolled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care 2010; 33: 1598-1601.
50. Hilbig R, Rahmann H. Comparative autoradiographic investigations on the tissue distribution of benfotiamine versus thiamine in mice. Arzneimittelforschung 1998; 48:461-8.
51. Babaei-Jadidi R, Karachalias N, Kupich C, Ahmed N, Thornalley PJ. High-dose thiamine therapy counters dyslipidaemia in streptozotocin-induced diabetic rats. Diabetologia 2004; 47: 2235-46.
52. Karachalias N, Babaei-Jadidi R, Kupich C, Ahmed N, Thornalley PJ: High-dose thiamine therapy counters dyslipidemia and advanced glycation of plasma protein in streptozotocin-induced diabetic rats. Ann N Y Acad Sci 2005; 1043: 777-83.
53. Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003; 9: 294-9.
54. Berrone E, Beltramo E, Solimine C, Ape AU, Porta M. Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose. J Biol Chem 2006; 281(14): 9307-13.
55. Schmid U, Stopper H, Heidland A, Schupp N. Benfotiamine exhibits direct antioxidative capacity and prevents induction of DNA damage in vitro. Diabetes Metab Res Rev 2008; 24: 371-7.
56. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 2003; 52: 2110-20.
57. Stracke H, Hammes HP, Werkmann D, Mavrakis K, Bitsch I, Netzel M, et al. Efficacy of benfotiamine versus thiamine on function and glycation products of peripheral nerves in diabetic rats. Exp Clin Endocrinol Diabetes 2001; 109: 330-6.
58. Wu S, Ren J. Benfotiamine alleviates diabetes-induced cerebral oxidative damage independent of advanced glycation end-product, tissue factor and TNF-alpha. Neurosci Lett 2006; 394:158-62.
59. Gadau S, Emanueli C, Van LS, Graiani G, Todaro M, Meloni M, et al. Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis. Diabetologia 2006; 49:405-20.
60. Balakumar P, Sharma R, Singh M. Benfotiamine attenuates nicotine and uric acid-induced vascular endothelial dysfunction in the rat. Pharmacol Res 2008; 58 (5-6): 356-63.
61. Koltai MZ, Pósa I, Winkler G, Kocsis E, Pogátsa G. The preventive effect of benfotiamine on the development of cardiac autonomic neuropathy in diabetic dogs. Hung Arch Int Med 1997; 50, 443-8.
62. Kihm LP, Muller-Krebs S, Klein J, Ehrlich G, Mertes L, Gross ML, et al. Benfotiamine protects against peritoneal and kidney damage in peritoneal dialysis. J Am Soc Nephrol 2011; 22: 914-26.
63. Rathanaswami P, Pourany A, Sundaresan R. Effects of thiamine deficiency on the secretion of insulin and the metabolism of glucose in isolated rat pancreatic islets. Biochem Int 1991; 25:577-83.
64. Rathanaswami P, Sundaresan R. Effects of thiamine deficiency on the biosynthesis of insulin in rats. Biochem Int 1991; 24:1057-62.
65. Haupt E, Ledermann H, Kopcke W. Benfotiamine in the treatment of diabetic polyneuropathy-a three-week randomized, controlled pilot study (BEDIP study). Int J Clin Pharmacol Ther 2005; 43: 71-7.
66. Stracke H, Gaus W, Achenbach U, Federlin K, Bretzel RG. Benfotiamine in Diabetic Polyneuropathy (BENDIP): Results of a Randomised, Double Blind, Placebo-controlled Clinical Study. Exp Clin Endocrinol Diabetes 2008; 116: 600-5.
67. Fraser DA, Diep LM, Hovden IA, Nilsen KB, Sveen KA, Seljeflot I, et al. The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial. Diabetes Care 2012; 35:1095-7.
68. Ziegler D, Tesfaye S, Kempler P. Comment on Fraser et al,. The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: A 24-month, double-blind, randomized, placebocontrolled trial. Diabetes Care 2012; in press.
69. Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010; 33: 2285-93.
70. Pop-Busui R, Herman WH, Feldman EL, Low PA, Martin CL, Cleary PA, et al. DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Curr Diab Rep 2010; 10: 276-82.
71. Ekberg K, Johansson BL. Effect of C-peptide on diabetic neuropathy in patients with type 1 diabetes. Exp Diabetes Res 2008; 2008:457912.
72. Winkler G, Pal B, Nagybeganyi E, Ory I, Porochnavec M, Kempler P. Effectiveness of different benfotiamine dosage regimens in the treatment of painful diabetic neuropathy. Arzneimittelforschung 1999; 49:220-4.
73. Lederman H, Wiedey KD. Treatment of manifest diabetic polyneuropathy. Therapiewoche 1989; 39: 1445-9.
74. Stracke H, Lindemann A, Federlin K. A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. Exp Clin Endocrinol Diabetes 1996; 104: 311-6.
75. Rieck J, Halkin H, Almog S, Seligman H, Lubetsky A, Olchovsky D, et al. Urinary loss of thiamine is increased by low doses of furosemide in healthy volunteers. J Lab Clin Med 1999; 134: 238-43.
76. Seligmann H, Halkin H, Rauchfleisch S, Kaufmann N, Motro M, Vered Z, et al. Thiamine deficiency in patients with congestive heart failure receiving long-term furosemide therapy: a pilot study. Am J Med 1991; 91:151-5.
77. Hobara R, Kato H, Sakamoto K. Effect of thiamine and thiamine levels on experimental alloxan induced diabetes mellitus. Jpn J Pharmacol 1983; 33:27-31.
78. Saito N, Kimura M, Kuchiba A, Itokawa Y. Blood thiamine levels in outpatients with diabetes mellitus. J Nutr Sci Vitaminol (Tokyo) 1987; 33: 421-30.
79. Jermendy G. Evaluating thiamine deficiency in patients with diabetes. Diab Vasc Dis Res 2006; 3: 120-1.
80. Clark JA, Burny I, Sarnaik AP, Audhya TK. Acute thiamine deficiency in diabetic ketoacidosis: Diagnosis and management. Pediatr Crit Care Med 2006; 7: 595-9.
81. Ashokkumar B, Vaziri ND, Said HM. Thiamin uptake by the human-derived renal epithelial (HEK-293) cells: cellular and molecular mechanisms. Am J Physiol Renal Physiol 2006; 291:F796-F805.
82. Thornalley PJ, Babaei-Jadidi R, Al Ali H, Rabbani N, Antonysunil A, Larkin J, et al. High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia 2007; 50: 2164-70.
83. Shimon I, Almog S, Vered Z, Seligmann H, Shefi M, Peleg E, et al. Improved left ventricular function after thiamine supplementation in patients with congestive heart failure receiving long-term furosemide therapy. Am J Med 1995; 98: 485-90.
84. Stirban A, Negrean M, Stratmann B, Gawlowski T, Horstmann T, Gotting C, et al. Benfotiamine prevents macro-and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 2006; 29: 2064-71.
85. Rabbani N, Alam SS, Riaz S, Larkin JR, Akhtar MW, Shafi T, et al. High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled pilot study. Diabetologia 2009; 52:208-12.
86. Du X, Edelstein D, Brownlee M. Oral benfotiamine plus alphalipoic acid normalises complication-causing pathways in type 1 diabetes. Diabetologia 2008; 51:1930-2.
87. Bierhaus A, Fleming T, Stoyanov S, Leffler A, Babes A, Neacsu C, Sauer SK, et al. Methylglyoxal modification of Na(v)1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med 2012; 18, 926-33.
88. Golbidi S, Badran M, Laher I. Diabetes and alpha lipoic acid. Front Pharmacol 2011; 2: 69.
89. Vallianou N, Evangelopoulos A, Koutalas P. Alpha-lipoic acid and diabetic neuropathy. Rev Diabet Stud 2009; 6: 230-6
90. Poh ZX, Goh KP. A current update on the use of alpha lipoic acid in the management of type 2 diabetes mellitus. Endocr Metab Immune Disord Drug Targets 2009; 9: 392-8.
91. Gorca A, Huk-Kolega H, Piechota A, Kleniewska P, Ciejka E, Skibska B. Lipoic acid-biological activity and therapeutic potential. Pharmacol Rep 2011; 63: 849-58.
92. Skalská S, Kucera P, Goldenberg Z, Stefek M, Kyselová Z, Jariabka P, et al. Neuropathy in a rat model of mild diabetes induced by multiple low doses of streptozotocin: effects of the antioxidant stobadine in comparison with a high-dose alpha-lipoic acid treatment. Gen Physiol Biophys 2010; 29: 50-8.
93. Lee WY, Orestes P, Latham J, Naik AK, Nelson MT, Vitko I, et al. Molecular mechanisms of lipoic acid modulation of T-type calcium channels in pain pathway. J Neurosci 2009; 29: 9500-9
94. Teichert J, Tuemmers T, Achenbach H, Preiss C, Hermann R, Ruus P, et al. Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease. J Clin Pharmacol 2005; 45: 313-28.
95. Heinisch BB, Francesconi M, Mittermayer F, Schaller G, Gouya G, Wolzt M, et al. Alpha-lipoic acid improves vascular endothelial function in patients with type 2 diabetes: a placebo-controlled randomized trial, Eur J Clin Invest 2010; 40: 148-54.
96. Strokov IA, Manukhina EB, Bakhtina LY, Malyshev IY, Zoloev GK, Kazikhanova SI, et al. The function of endogenous protective systems in patients with insulin-dependent diabetes mellitus and polyneuropathy: effect of antioxidant therapy. Bull Exp Biol Med 2000; 130: 986-90.
97. Haak E, Usadel KH, Kusterer K, Amini P, Frommeyer R, Tritschler HJ, et al. Effects of alpha-lipoic acid on microcirculation in patients with peripheral diabetic neuropathy. Exp Clin Endocrinol Diabetes 2000; 108:168-74.
98. Sola S, Mir MQ, Cheema FA, Khan-Merchant N, Menon RG, Parthasarathy S, et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation 2005; 111: 343-8.
99. Kim HS, Kim HJ, Park KG, Kim YN, Kwon TK, Park JY, et al. Alpha-lipoic acid inhibits matrix metalloproteinase-9 expression by inhibiting NF-kappaB transcriptional activity. Exp Mol Med 2007; 39: 106-13.
100. Yi X, Kim K, Yuan W, Xu L, Kim HS, Homeister JW, et al. Mice with heterozygous deficiency of lipoic acid synthase have an increased sensitivity to lipopolysaccharide-induced tissue injury. J Leukoc Biol 2009; 85:146-53.
101. Ziegler D, Nowak H, Kempler P, Vargha P, Low A. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alphalipoic acid: a metaanalysis. Diabet Med 2004; 21:114-21.
102. Ford I, Cotter MA, Cameron NE, Greaves M. The effects of treatment with alpha-lipoic acid or evening primrose oil on vascular hemostatic and lipid risk factors, blood flow, and peripheral nerve conduction in streptozocin-diabetic rat. Metabolism 2001; 50: 868-75.
103. Ziegler D, Hanefeld M, Ruhnau KJ, Meissner HP, Lobisch M, Schütte K, et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alfa-lipoic acid. A 3 week multicenter randomized controlled trial (ALADIN Study). Diabetologia 1995; 38:1425-33.
104. Ametov AS, Barinov A, Dyck P, Hermann R, Kozlova N, Litchy W, et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid. Diabetes Care 2003; 26: 770-6.
105. Ruhnau KJ, Meissner HP, Finn JR, Reljanovic M, Lobisch M, Schütte K, et al. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med 1999; 16:1040-3.
106. Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneruopathy: the SYDNEY 2 trial. Diabetes Care 2006; 29:2365-70.
107. Reljanovic M, Reichel G, Lobisch M, Schuette K, Moller W, Tritschler HJ, et al Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alfa-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alfa Lipoic Acid in Diabetic Neuropathy. Free Radic Res 1999; 31:171-9.
108. Ziegler D, Low PA, Litchy WJ, Boulton AJ, Vinik AI, Freeman R, et al. Efficacy and safety of antioxidant treatment with β-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care 2011; 34: 2054-60.
109. Mijnhout GS, Kollen BJ, Alkhalaf A, Kleefstra N, Bilo HJ. Alpha lipoic Acid for symptomatic peripheral neuropathy in patients with diabetes: a metaanalysis of randomized controlled trials. Int J Endocrinol 2012; 2012: 456279. doi: 10.1155/2012/456279
110. Tankova T, Cherninkova S, Koev D. Treatment for diabetic mononeuropathy with alpha lipoic acid. Int J Clin Pract 2005; 59: 645-50.
111. Ziegler D, Schatz H, Conrad F, Gries FA, Ulrich H, Reichel G, et al. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Diabetes Care 1997; 20: 369-73.
112. Ziegler D, Hanefeld M, Ruhnau KJ, Hasche H, Lobisch M, Schütte K, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 1999; 22:1296-1301.
113. McIlduff CE, Rutkove SB. Critical appraisal of the use of alpha lipoic acid (thioctic acid) in the treatment of symptomatic diabetic polyneuropathy. Ther Clin Risk Manag 2011; 7: 377-85.
114. Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM. Alphalipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta 2009; 1790: 1149-60.
115. Singh U, Jialal I. Alpha-lipoic acid supplementation and diabetes. Nutr Rev 2008; 66:646-57.
116. Kunika T, Senga Y, Senga H, Weiner M. Nature of enhanced mitochondrial oxidative metabolism by a calf blood extract. 1991; J Cell Physiol 146: 148-55.
117. Obermaier-Kusser B, Muhlbacher C, Mushack J, Seffer E, Ermel B, Machicao F. Further evidence for a two-step model of glucosetransport regulation: inositol phosphate oligosaccharides regulate glucose-carrier activity. Biochem J 1989; 261(3): 699-705.
118. Jacob S, Dietze GJ, Machicao F, Kuntz G, Augustin HJ. Improvement of glucose metabolism in patients with type II diabetes after treatment with hemodialysate. Arzneimittelforschung 1996; 46: 269-272.
119. Jensen W, Beck E. Treatment of the diabetic polyneuropathy: controlled double blind study. Med Welt 1987; 38: 838-41.
120. Ziegler D, Movsesyan L, Mankovsky B, Gurieva I, Abylaiuly Z, Strokov I. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care 2009; 32: 1479-84.
121. Cotter MA, Ekberg K, Wahren J, Cameron NE. Effects of proinsulin C-peptide in experimental diabetic neuropathy: vascular actions and modulation by nitric oxide synthase inhibition. Diabetes 2003; 52: 1812-17.
122. Johansson BL, Berg K, Fernqvist-Forbes E, Kernell A, Odergren T, Wahren J. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with type 1 diabetes mellitus. Diabet Med 2000; 17:181-9.
123. Dobrawsky RT, Rouen S, Yu C. Altered neurotrophism in diabetic neuropathy: spelunking the caves of peripheral nerve. J Pharmacol Exp Ther 2005; 313: 485-91.
124. Apfel SC, Schwartz S, Adornato BT, Freeman R, Biton V, Rendell M et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. rhNGF Clinical Investigator Group. JAMA 2000; 284: 2215-21.
125. Chattopadhyay M, Krisky D, Wolfe D, Glorioso JC, Mata M, Fink DJ. HSV-mediated gene transfer of vascular endothelial growth factor to dorsal ganglia prevents diabetic neuropathy. Gene Ther 2005; 12:1377-84.
126. Ropper AH, Gorson KC, Gooch CL, Weinberg DH, Pieczek A, Ware JH, et al. Vascular endothelial growth factor gene transfer for diabetic polyneuropathy: a randomized, double-blinded trial. Ann Neurol. 2009; 65 (4): 386-93.
127. Sima AA, Calvani M, Mehra M. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. Diabetes Care 2005; 28: 89-94.
128. Cameron NE, Cotter MA. Effects of chronic treatment with a nitric oxide donor on nerve conduction abnormalities and endoneurial blood flow in streptozotocin-diabetic rats. Eur J Clin Invest. 1995; 25(1):19-24.
129. Yuen KC, Baker NR, Rayman G. Treatment of chronic painful diabetic neuropathy with isosorbide dinitrate spray: a double-blind placebo-controlled cross-over study. Diabetes Care. 2002; 25 (10):1699-703.
130. Agrawal RP, Choudhary R, Sharma P, Sharma S, Beniwal R, Kaswan K, et al. Glyceryl trinitrate spray in the management of painful diabetic neuropathy: a randomized double blind placebo controlled cross-over study. Diabetes Res Clin Pract. 2007; 77(2): 161-7
131. Rayman G, Baker NR, Krishnan ST. Glyceryl trinitrate patches as an alternative to isosorbide dinitrate spray in the treatment of chronic painful diabetic neuropathy. Diabetes Care 2003; 26: 2697-8.
132. Reja A, Tesfaye S, Harris ND, Ward JD. Is ACE inhibition with lisinopril helpful in diabetic neuropathy? Diabet Med. 1995;12 (4):307-9.
133. Malik RA, Williamson S, Abbott C, Carrington AL, Iqbal J, Schady W, et al. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised doubleblind controlled trial. Lancet. 1998; 352 (9145): 1978-81.
134. Nicholson B, Verma S. Comorbidities in chronic neuropathic pain. Pain Med. 2004; Suppl 1: S9-S27.
135. Boulton AJ. Is duloxetine more effective than amitriptyline for painful diabetic neuropathy? Curr Diab Rep 2011; 11: 230-2.
136. Hovaguimian A, Gibbons CH. Clinical Approach to the Treatment of Painful Diabetic Neuropathy Ther Adv Endocrinol Metab 2011; 2: 27-38.
137. Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev 2012; 28: 8-14.
138. Vinik A. C: Use of antiepileptic drugs in the treatment of chronic painful diabetic neuropathy. J Clin Endocrinol Metab 2005; 90: 4936-45.
139. Vinik A. Diabetic neuropathy in older adults. Clin Geriatr Med 2008; 24: 407-39.
140. Ziegler D. Painful Diabetic Neuropathy. Advantage of novel drugs over old drugs? Diabetes Care 2009; 32: S414-9.
141. Bril V, England JD, Franklin GM, Backonja M, Cohen JA, Del Toro DR, et al. Evidence-based guideline: treatment of painful diabetic neuropathy--report of the American Association of Neuromuscular and Electrodiagnostic Medicine, the American Academy of Neurology, and the American Academy of Physical Medicine & Rehabilitation. Muscle Nerve 2011; 43: 910-7.
142. Cheng JK, Lee SZ, Yang JR, Wang CH, Liao YY, Chen CC et al. Does gabapentin act as an agonist at native GABA(B) receptors? J Biomed Sci 2004; 11: 346-55.
143. Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996; 271: 5768-76.
144. Dooley DJ, Taylor CP, Donevan S, Feltner D. Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol Sci 2007; 28: 75-82.
145. Taylor CP. Mechanisms of analgesia by gabapentin and pregabalincalcium channel alpha2-delta [Cavalpha2-delta] ligands. Pain 2009; 142: 13-6.
146. Taylor CP, Angelotti T, Faumanc E. Pharmacology and mechanism of action of pregabalin: The calcium channel alpha2-delta subunit as a target for antiepileptic drug discovery. Epilepsy Res 2007; 73: 137-50.
147. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998; 280: 1831-6.
148. Gorson KC, Schott C, Herman R, Ropper AH, Rand WM. Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. J Neurol Neurosurg Psychiatry 1999; 66: 251-2.
149. Perez HE, Sanchez GF. Gabapentin therapy for diabetic neuropathic pain. Am J Med 2000; 108: 689.
150. Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 1999; 159: 1931-7.
151. Dallocchio C, Buffa C, Mazzarello P, Chiroli S. Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study. J Pain Symptom Manage 2000; 20: 280-5.
152. Chou R, Carson S, Chan BK. Gabapentin versus tricyclic antidepressants for diabetic neuropathy and post-herpetic neuralgia: discrepancies between direct and indirect meta-analyses of randomized controlled trials. J Gen Intern Med 2009; 24: 178-88.
153. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005; 352: 1324-34.
154. Sandercock D, Cramer M, Biton V, Cowles VE. A gastroretentive gabapentin formulation for the treatment of painful diabetic peripheral neuropathy: Efficacy and tolerability in a double-blind, randomized, controlled clinical trial. Diabetes Res Clin Pract 2012; doi:10.1016/j.diabres.2012.03.010
155. Ermis N, Gullu H, Caliskan M, Unsal A, Kulaksizoglu M, Muderrisoglu H. Gabapentin therapy improves heart rate variability in diabetic patients with peripheral neuropathy. J Diabetes Complications 2010; 24: 229-33.
156. Lindsay TJ, Rodgers BC, Savath V, Hettinger K. Treating diabetic peripheral neuropathic pain. Am Fam Physician 2010; 82: 151-8.
157. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther 2003; 25: 81-104.
158. Tesfaye S, Vileikyte L, Rayman G, Sindrup S, Perkins B, Baconja M, et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev 2011; 27: 629-38.
159. Ziegler D. Painful diabetic neuropathy: treatment and future aspects. Diabetes Metab Res Rev 2008; 24: S52-7.
160. Shneker BF, McAuley JW. Pregabalin: a new neuromodulator with broad therapeutic indications Ann Pharmacother 2005; 39: 2029-37.
161. Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet 2010; 49: 661-9.
162. Guay DR. Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? Am J Geriatr Pharmacother 2005; 3: 274-87.
163. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004; 110: 628-38.
164. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004; 63: 2104-10.
165. Satoh J, Yagihashi S, Baba M, Suzuki M, Arakawa A, Yoshiyama T, et al. Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial. Diabet Med 2011; 28: 109-16.
166. Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 2005; 6: 253-60.
167. Tölle T, Freynhagen R, Versavel M, Trostmann U, Young JP. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: A randomized, double-blind study. Eur Pain 2008; 12: 203-13.
168. Arezzo JC, Rosenstock J, Lamoreaux L, Pauer L Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol 2008; 8: 33-46.
169. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible-and fixed-dose regimens. Pain 2005; 115: 254-63.
170. Baron R, Brunnmüller U, Brasser M, May M, Binder A. Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: Open-label, non-comparative, flexible-dose study. Eur J Pain 2008; 12: 850-8.
171. Jiang W, Ladd S, Martsberger C, Feinglos M, Spratt SE, Kuchibhatla M, et al. Effects of pregabalin on heart rate variability in patients with painful diabetic neuropathy. J Clin Psychopharmacol. 2011; 31: 207-13.
172. Bansal D, Bhansali A, Hota D, Chakrabarti A, Dutta P. Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial. Diabet Med 2009; 26: 1019-26.
173. Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy. Diabetes Care 2008; 31: 1448-54.
174. Daousi C, Nurmikko TJ. Painful diabetic neuropathy. In: Stannard C, Kalso E, Ballantyne J, Eds, Evidence-Based Chronic Pain Management. Blackwell Publishing. 2010; 204-21.
175. Kochar DK, Jain N, Agarwal RP, Srivastava T, Agarwal P, Gupta S. Sodium valproate in the management of painful neuropathy in type 2 diabetes-a randomized placebo controlled study. Acta Neurol Scand 2002; 106: 248-52.
176. Kochar DK, Rawat N, Agrawal RP, Vyas A, Beniwal R, Kochar SK, et al. Sodium valproate for painful diabetic neuropathy: a randomized double-blind placebo-controlled study. QJM 2004; 97: 33-8.
177. Otto M, Bach FW, Jensen TS, Sindrup SH. Valproic acid has no effect on pain in polyneuropathy: a randomized, controlled trial. Neurology 2004; 62: 285-8.
178. Dogra S, Beydoun S, Mazzola J, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: a randomized, placebocontrolled study. Eur J Pain 2005; 9: 543-54.
179. Beydoun A, Shaibani A, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: results of a dose-ranging study. Acta Neurol Scand 2006; 113: 395-404.
180. Grosskopf J, Mazzola J, Wan Y, Hopwood M. A randomized, placebo-controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurol Scand 2006; 114: 177-80.
181. Curia G, Biagini G, Perucca E, Avoli M. Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs 2009; 23: 555-68.
182. Rauck RL, Shaibani A, Biton V, Simpson J, Koch B. Lacosamide in painful diabetic peripheral neuropathy: a Phase 2 double-blind placebo-controlled study. Clin J Pain 2007; 23: 150-8.
183. Shaibani A, Biton V, Rauck R, Koch B, Simpson J. Long-term oral lacosamide in painful diabetic neuropathy: a two-year openlabel extension trial. Eur J Pain 2009; 13: 458-63.
184. Shaibani A, Fares S, Selam J-L, Simpson J, Sen D, Bongardt S. Lacosamide in painful diabetic neuropathy: an 18-week doubleblind placebo-controlled trial. J Pain 2009; 10: 818-28.
185. Wymer JP, Simpson J, Sen D, Bongardt S, on behalf of the Lacosamide SP742 Study Group. Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebocontrolled trial of fixed-dose regimens. Clin J Pain 2009; 25: 376-385.
186. Ziegler D, Hidvégi T, Gurieva I, Bongardt S, Freynhagen R, Sen D, et al. Efficacy and safety of lacosamide in painful diabetic neuropathy. Diabetes Care 2010; 33: 839-41.
187. European Medicines Agency Pre-authorisation evaluation of Medicines for Human Use. Doc. Ref: EMEA/CHMP/658067/2008. Withdrawal Assessment Report for Lacosamide Pain UCB Pharma. International Nonproprietary Name: lacosamide. Procedure No. EMEA/H/C/894. http://www.ema.europa.eu/docs/en_GB/document_library/Appl ication_withdrawal_assessment_report/2010/01/WC500064326.pdf. London, 5 December 2008. Accessed on the 1st of June 2012.
188. Eisenberg E, Lurie Y, Braker C, Daoud D, Ishay A. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology 2001; 57: 505-9.
189. Vinik AI, Tuchman M, Safirstein R, Corder C, Kirby L, Wilks K, et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebocontrolled studies. Pain 2007; 128: 169-79.
190. Thienel U, Neto W, Schwabe SK, Vijapurkar U, Topiramate Diabetic Neuropathic Pain Study Group. Topiramate in painful diabetic polyneuropathy: findings from three double-blind, placebocontrolled trials. Acta Neurol Scand 2004; 110: 221-31.
191. Raskin P, Donofrio PD, Rosenthal NR, Hewitt DJ, Jordan DM, Xiang J, et al. Topiramate vs. placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology 2004; 63: 865-73.
192. Donofrio PD, Raskin P, Rosenthal NR, Hewitt DJ, Jordan DM, Xiang J, et al. Safety and effectiveness of topiramate for the management of painful diabetic peripheral neuropathy in an open-label extension study. Clin Ther 2005; 27: 1420-31.
193. Chan HN, Fam J, Ng BY. Use of antidepressants in the treatment of chronic pain. Ann Acad Med Singapore 2009; 38: 974-9.
194. Vileikyte L, Peyrot M, Gonzalez JS, Rubin RR, Garrow AP, Stickings D, et al. Predictors of depressive symptoms in persons with diabetic peripheral neuropathy: a longitudinal study. Diabetologia 2009; 52: 1265-73.
195. Costigan M, Scholz J, Woolf CJ. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci 2009; 32: 1-32.
196. Jefferies K. Treatment of Neuropathic Pain. Semin Neurol 2010; 30: 425-32.
197. Ziegler D, Pritchett YL, Wang F, Desaiah D, Robinson MJ, Hall JA, et al. Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain. Diabetes Care 2007; 30: 664-9.
198. Zilliox L, Russell JW. Maintaining efficacy in the treatment of diabetic peripheral neuropathic pain: role of duloxetine. Diabetes Metab Syndr Obes 2010; 3: 7-17.
199. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005; 116: 109-18.
200. Raskin J, Pritchett YL, Wang F, D'Souza DN, Waninger AL, Iyengare S, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005; 6: 346-56.
201. Wernicke JF, Pritchett YL, D'Souza DN, Waninger A, Tran P, Iyengar S, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006; 67: 1411-20.
202. Wernicke JF, Prakash A, Kajdasz DK, Houston J. Safety and tolerability of duloxetine treatment of diabetic peripheral neuropathic pain between patients with and without cardiovascular conditions. J Diabetes Complications 2009; 23: 349-59.
203. Skljarevski V, Desaiah D, Zhang Q, Chappell AS, Detke MJ, Gross JL, et al. Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain. Diabetes Metab Res Rev 2009; 25: 623-31.
204. Raskin J, Wang F, Pritchett YL, Goldstein DJ. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month openlabel safety study. Pain Med 2006; 7: 373-85.
205. Raskin J, Smith TR, Wong K, Pritchett YL, D'Souza DN, Iyengar S, et al. Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain. J Palliat Med 2006; 9: 29-40.
206. Wernicke JF, Wang F, Pritchett YL, Smith TR, Raskin J, D'Souza DN, et al. An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain. Pain Med 2007; 8: 503-13.
207. Kaur H, Hota D, Bhansali A, Dutta P, Bansal D, Chakrabarti A. A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial. Diabetes Care 2011; 34: 818-22.
208. Gaynor P, McCarberg B, Zheng W, Shoemaker S, Duenas H. Weight change with long-term duloxetine use in chronic painful conditions: an analysis of 16 clinical studies. Int J Clin Pract 2011; 65: 341-9.
209. Hardy T, Sachson R, Shen S, Armbruster M, Boulton AJ. Does treatment with duloxetine for neuropathic pain impact glycemic control? Diabetes Care 2007; 30: 21-6.
210. Perahia DG, Pritchett YL, Desaiah D, Raskin J. Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect? Int Clin Psychopharmacol 2006; 21: 311-7.
211. Simpson DA. Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. J Clin Neuromusc Dis 2001; 3: 53-62.
212. Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology 2003; 60: 1284-9.
213. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlaxafine extended release in the treatment of painful diabetic neuropathy: a doubleblind, placebo-controlled study. Pain 2004; 110: 697-706.
214. Kadiroglu AK, Sit D, Kayabasi H, Tuzcu AK, Tasdemir N, Yilmaz ME. The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus. J Diabetes Complications 2008; 22: 241-5.
215. Sindrup SH, Gram LF, Brosen K, Eshoj O, Mogensen EF. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990; 42: 135-44.
216. Sindrup SH, Grodum E, Gram LF, Beck-Nielsen H. Concentrationresponse relationship in paroxetine treatment of diabetic neuropathy symptoms: a patient-blinded dose-escalation study. Therap Drug Monit 1991; 13: 408-14.
217. Sindrup SH, Bjerre U, Dejgaard A, Brosen K, Aes-Jorgensen T, Gram LF. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 1992; 52: 547-52.
218. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. New Engl J Med 1992; 326: 1250-6.
219. Max MB, Culnane M, Schafer SC, Gracely RH, Walther DJ, Smoller B, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987; 37: 589-96.
220. Kvinesdal B, Molin J, Froland A, Gram LF. Imipramine treatment of painful diabetic neuropathy. JAMA 1984; 251: 1727-30.
221. Max MB, Kishore-Kumar R, Schafer SC, Meister B, Gracely RH, Smoller B, et al. Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain 1991; 45: 3-9.
222. Sindrup SH, Gram LF, Skjold T, Grodum E, Brosen K, Beck-Nielsen H. Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study. Br J Clin Pharmacol 1990; 30: 683-91.
223. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 2003; 60: 927-34.
224. Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 2003; 105: 71-8.
225. Zin CS, Nissen LM, O'Callaghan JP, Duffull SB, Smith MT, Moore BJ. A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. J Pain 2010; 11: 462-71.
226. Harati Y, Gooch C, Swenson M, Edelman S, Greene D, Raskin P, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998; 50: 1842-6.
227. Harati Y, Gooch C, Swenson M, Edelman SV, Greene D, Raskin P, et al. Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy. J Diabetes Complicat 2000; 14: 65-70.
228. Sindrup SH, Andersen G, Madsen C, Smith T, Brosen K, Jensen TS. Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain 1999; 83: 85-90.
229. st of June 2012.
230. Selvarajah D, Gandhi R, Emery CJ, Tesfaye S. Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy. Diabetes Care 2010; 33: 128-30.
231. Kastrup J, Petersen P, Dejgard A, Angelo HR, Hilsted J. Intravenous lidocaine infusion-a new treatment of chronic painful diabetic neuropathy? Pain 1987; 28: 69-75.
232. Boas RA, Covino BG, Shahnarian A. Analgesic responses to i.v. lignocaine. Br J Anaesth 1982; 54: 501-5.
233. Argoff CE, Galer BS, Jensen MP, Oleka N, Gammaitoni AR. Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the Neuropathic Pain Scale. Curr Med Res Opin 2004; 20: S21-8.
234. Barbano RL, Herrmann DN, Hart-Gouleau S, Pennella-Vaughan J, Lodewick PA, Dworkin RH. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol 2004; 61: 914-8.
235. Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M. 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, noninferiority two-stage RCT study. Curr Med Res Opin 2009; 25: 1663-76.
236. Scheffler NM, Sheitel PL, Lipton MN. Treatment of painful diabetic neuropathy with capsaicin 0.075%. J Am Podiatr Med Assoc. 1991; 81: 288-93.
237. Tandan R, Lewis GA, Krusinski PB, Badger GB, Fries TJ. Topical capsaicin in painful diabetic neuropathy. Controlled study with long-term follow-up. Diabetes Care 1992; 15: 8-14.
238. Zhang WY, Li Wan Po A. The effectiveness of topically applied capsaicin. A meta-analysis. Eur J Clin Pharmacol 1994; 46: 517-22.
239. Mason L, Moore RA, Derry S, Edwards JE, McQuay HJ. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ 2004; (doi:10.1136/bmj.38042.506748) 328: 991.
240. Webster LR, Peppin JF, Murphy FT, Lu B, Tobias JK, Vanhove GF. Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain. Diabetes Res Clin Pract 2011; 93: 187-97.
241. Webster LR, Peppin JF, Murphy FT, Tobias JK, Vanhove GF. Tolerability of NGX-4010, a capsaicin 8% patch, in conjunction with three topical anesthetic formulations for the treatment of neuropathic pain. J Pain Res. 2012; 5: 7-13.
242. TM) in diabetic neuropathic pain patients: detection of distinct response groups. J Pain Res 2012; 5: 51.
243. Nolano M, Simone DA, Wendelschafer-Crabb G, Johnson T, Hazen E, Kennedy WR. Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain1999; 81: 135-45.
244. Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 2008; 64: 274-83.
245. Yuan RY, Sheu JJ, Yu JM, Chen WT, Tseng IJ, Chang HH, et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology 2009; 72: 1473-8.
246. van Sloten TT, Savelberg HH, Duimel-Peeters IG, Meijer K, Henry RM, Stehouwer CD, et al. Peripheral neuropathy, decreased muscle strength and obesity are strongly associated with walking in persons with type 2 diabetes without manifest mobility limitations. Diabetes Res Clin Pract 2011; 91: 32-9.
247. Hung JW, Liou CW, Wang PW, Yeh SH, Lin LW, Lo SK, et al. Effect of 12-week tai chi chuan exercise on peripheral nerve modulation in patients with type 2 diabetes mellitus. J Rehabil Med 2009; 41: 924-9.
248. Ites KI, Anderson EJ, Cahill ML, Kearney JA, Post EC, Gilchrist LS. Balance interventions for diabetic peripheral neuropathy: a systematic review. J Geriatr Phys Ther 2011; 34: 109-16.
249. Ajimsha MS, Paul JK, Chithra S. Efficacy of stability trainer in improving balance in type II diabetic patients with distal sensory neuropathy. J Diabetol 2012; 1: 6.
250. Pataky Z, de León Rodriguez D, Allet L, Golay A, Assal M, Assal JP, et al. Biofeedback for foot offloading in diabetic patients with peripheral neuropathy. Diabet Med 2010; 27: 61-4.
251. Gillespie EA, Gillespie BW, Stevens MJ. Painful diabetic neuropathy. Impact of an alternative approach. Diabetes Care 2007; 30: 999-1001.
252. Abuaisha BB, Constanzi JB, Boulton AJM. Acupuncture for the treatment of chronic painful diabetic neuropathy: a long-term study. Diabetes Res Clin Pract 1998; 39: 115-21.
253. Ahn AC, Bennani T, Freeman R, Hamdy O, Kaptchuk TJ. Two styles of acupuncture for treating painful diabetic neuropathy-a pilot randomised control trial. Acupunct Med 2007; 25: 11-17
254. Chaudhry V, Stevens JC, Kincaid J, So YT. Practice Advisory: utility of surgical decompression for treatment of diabetic neuropathy: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 1805-8.
255. Dellon AL. Diabetic neuropathy: medical and surgical approaches. Clin Podiatr Med Surg 2007; 24: 425-8.
256. Kumar SP, Adhikari P, Jeganathan PS, Misri ZK. Surgical management of painful diabetic peripheral neuropathy: a focused review. Int J Neurol Neurosurg 2012; 4: 21-5.
257. Leonard DR, Farooqu MH, Myers S. Restoration of sensation, reduced pain, and improved balance in subjects with diabetic peripheral neuropathy: a double-blind, randomised placebo-controlled study with monochromatic infrared treatment. Diabetes Care 2004; 27: 168-72.
258. TM) decreases falls and the fear of falling and improves activities of daily living in seniors. Age Ageing 2006; 35: 11-6.
259. Lavery LA, Murdoch DP, Williams J, Lavery DC. Does anodyne light therapy improve peripheral neutopathy in diabetes? A doubleblind, sham-controlled, randomized trial to evaluate monochromatic infrared photoenergy. Diabetes Care 2008; 31: 316-21.
260. Zinman LH, Ngo M, Ng ET, Gogov S, Bril V. Low-intensity laser therapy for painful symptoms of diabetic sensorimotor polyneuropathy: a controlled trial. Diabetes Care 2004; 27: 921-4.
261. Weintraub MI, Wolfe GI, Barohn RA, Cole SP, Parry GJ, Hayat G, et al. Static magnetic field therapy for symptomatic diabetic neuropathy: a randomized, double-blind, placebo-controlled trial. Arch Phys Med Rehabil 2003; 84: 736-46.
262. Weintraub MI, Herrmann DN, Smith AG, Backonja MM, Cole SP. Pulsed electromagnetic fields to reduce diabetic neuropathic pain and stimulate neuronal repair: a randomized controlled trial. Arch Phys Med Rehabil 2009; 90: 1102-9.
263. Kumar D, Marshall HJ. Diabetic peripheral neuropathy: amelioration of pain with transcutaneous electrostimulation. Diabetes Care 1997; 20: 1702-5.
264. Julka IS, Alvaro M, Kumar D. Beneficial effects of electrical stimulation on neuropathic symptoms in diabetes patients. J Foot Ankle Surg 1998; 37: 191-4.
265. Kumar D, Alvaro MS, Julka IS, Marshall HJ. Diabetic peripheral neuropathy. Effectiveness of electrotherapy and amitriptyline for symptomatic relief. Diabetes Care 1998; 21: 1322-5.
266. Oyibo S, Breislin K, Boulton AJM. Electrical stimulation therapy through stocking electrodes for painful diabetic neuropathy: a double-blind controlled crossover study. Diabet Med 2004; 21: 940-4.
267. Forst T, Nguyen M, Forst S, Disselhoff B, Pohlmann T, Pfützner A. Impact of low frequency transcutaneous electrical nerve stimulation on symptomatic diabetic neuropathy using the new Salutaris device. Diabetes Nutr Metab 2004; 17: 163-8.
268. Dubinsky RM, Miyasaki J. Assessment: efficacy of transcutaneous electric nerve stimulation in the treatment of pain in neurologic disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010; 74: 173-6.
269. Hamza MA, White PF, Craig WF, Ghoname ES, Ahmed HE, Proctor TJ, et al. Percutaneous electrical nerve stimulation: a novel analgesic therapy for diabetic neuropathic pain. Diabetes Care 2000; 23: 365-70
270. Pieber K, Herceg M, Paternostro-Sluga T. Electrotherapy for the treatment of painful diabetic peripheral neuropathy: a review. J Rehabil Med 2010; 42: 289-95.
271. Reichstein L, Labrenz S, Ziegler D, Martin S. Effective treatment of symptomatic diabetic polyneuropathy by high frequency external muscle stimulation. Diabetologia 2005; 48: 824-8.
272. Bosi E, Conti M, Vermigli C, Cazzetta G, Peretti E, Cordoni MC, et al. Effectiveness of frequency modulated electromagnetic neural stimulation in the treatment of diabetic peripheral neuropathy. Diabetologia 2005; 48: 817-23.
273. Tesfaye S, Watt J, Benbow SJet al., Pang KA, Miles J, MacFarlane IA Electrical spinal-cord stimulation for painful diabetic peripheral neuropathy. Lancet 1996; 348: 1698-701.
274. Daousi C, Benbow SJ, MacFarlane IA. Electrical spinal cord stimulation in the long-term treatment of chronic painful diabetic neuropathy. Diabet Med 2005; 22: 393-8.